ArticleAmerican journal of hematology2026
Limited Survival Benefit and High Healthcare Utilization With AML-Directed Therapy in Older Patients With TP53 -Mutated Acute Myeloid Leukemia.
Tina Y Zhang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.